An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of ND-003 in Patients With Advanced Solid Cancers
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Li Zhang, PhD
Sun Yat-sen University
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
21 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- the First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China
- Gansu Provincial Cancer Hospital
Lanzhou, Gansu, China
- the First Hospital of Lanzhou University
Lanzhou, Gansu, China
- Sun Yat-Sen University Cancer Center
Guangzhou, Guangdong, China
- the Sixth Affiliated Hospital of Sun Yat-Sen University
Guangzhou, Guangdong, China
- Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center
Shenzhen, Guangdong, China
- Zhanjiang Central Hospital, Guangdong Medical University
Zhanjiang, Guangdong, China
- Guangxi Medical University Cancer Hospital
Nanning, Guangxi, China
- the Affiliated Hospital of Guizhou Medical University
Guiyang, Guizhou, China
- Tongji Hospital Tongji Medical College of Hust
Wu’an, Hubei, China
- Hunan Cancer Hospital
Changsha, Hunan, China
- Jiangxi Cancer Hospital
Nanchang, Jiangxi, China
- the First Hospital of China Medical University
Shenyang, Liaoning, China
- General Hospital of Ningxia Medical University
Yinchuan, Ningxia, China
- Shandong Cancer Hospital & Institute
Jinan, Shandong, China
- Linyi Cancer Hospital
Linyi, Shandong, China
- Sichuan Cancer Hospital
Chengdu, Sichuan, China
- the Second People'S Hospital of Neijiang
Neijiang, Sichuan, China
- Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China
- Yunnan Cancer Hospital
Kunming, Yunnan, China
- Sir Run Run Shaw Hospital
Hangzhou, Zhejiang, China
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 4 Feb 2024
- Primary completion
- 31 Dec 2025
- Completion
- 30 Jun 2026
- Last update posted
- 15 Nov 2024
- Registered enrollment
- 96
- Registry id
- NCT06169579
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.